Pfizer Reports Second Phase III Failure in a Week: Torisel, Bevacizumab Combo for Advanced RCC

Drug Industry Daily
In the second late-stage failure for Pfizer this week, the company saw disappointing results for its Torisel when combined with Roche’s Avastin as a first-line treatment for advanced renal cell carcinoma (RCC).

To View This Article:


Subscribe To Drug Industry Daily